Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Trial details
- Registry ID
- NCT04845620
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)NCT04845620 | ARQT | Phase 3 | Completed | 2023-06-01Actual |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisNCT04773587 | ARQT | Phase 3 | Completed | 2022-08-30Actual |
| INM-755 (Cannabinol) Cream for Treatment of Epidermolysis BullosaNCT04908215 | INM | Phase 2 | Completed | 2023-04-03Actual |
| Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 | ARQT | Phase 3 | Recruiting | 2028-04-27Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |